Every Form 4 that Arrowhead Research Corporation (ARWR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ARWR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARWR filings page.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Adeoye Y. Olukotun reported a sale of 2,000 shares of common stock on 2026-08-18 in an open-market or private transaction at $86.96 per share. Following this transaction, he directly holds 31,600 shares, which the company notes include previously reported shares underlying Restricted Stock Units, some of which remain subject to vesting conditions.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Michael S. Perry reported a sale of 11,600 shares of common stock on 2026-08-18. The price reported is a weighted average of $87.30 per share, with individual trades between $87.20 and $87.44. Following this transaction, he directly holds 111,459 shares, which include previously reported shares underlying Restricted Stock Units, some of which remain subject to vesting conditions. The filing indicates the Rule 10b5-1 trading plan checkbox was not marked.
Arrowhead Pharmaceuticals director Matthew Gregory Cohen received an equity award. On the grant dated 06/15/2026, he acquired 11,882 shares of Common Stock underlying restricted stock units at no cash cost. These units vest over three years, and following the grant he directly holds 11,882 shares.
Arrowhead Pharmaceuticals director Hongbo Lu reported an open-market sale of company stock. On the reported date, Lu sold 2,970 shares of Arrowhead Pharmaceuticals common stock at a price of $76.88 per share in a single transaction.
The filing states this sale was made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares on a scheduled basis. After this transaction, Lu directly owned 52,012 shares of Arrowhead Pharmaceuticals common stock, which includes shares underlying previously granted restricted stock units, some of which are still subject to vesting conditions.
Arrowhead Pharmaceuticals’ Chief Financial Officer Daniel Joseph Apel sold 13,095 shares of common stock on April 22, 2026 in open-market transactions. The sales occurred at weighted average prices ranging from about $69.50 to $71.97 per share under a pre-established Rule 10b5-1 trading plan.
Following these sales, Apel directly holds 162,905 shares of Arrowhead common stock, which includes shares underlying previously reported restricted stock units that remain subject to vesting conditions. A portion of the disposition was made to satisfy tax withholding obligations related to equity compensation.
Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 10,000 shares of common stock in an open-market transaction at a weighted average price of $75.00 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Hamilton directly holds 226,958 shares, including shares underlying Restricted Stock Units, some of which remain subject to vesting conditions.
Arrowhead Pharmaceuticals' Chief Medical Officer sells shares under a preset plan. Chief Medical Officer James C. Hamilton executed an open-market sale of 10,000 shares of Arrowhead Pharmaceuticals common stock at a weighted average price of $64.19 per share on March 5, 2026, under a Rule 10b5-1 trading plan. After this transaction, he directly owned 236,958 shares, which include previously reported restricted stock units that remain subject to vesting conditions.
Arrowhead Pharmaceuticals Chief Medical Officer reports stock award. On 01/06/2026, Chief Medical Officer James C. Hamilton was granted 75,000 shares of Arrowhead Pharmaceuticals common stock underlying restricted stock units at a price of $0 per share.
These restricted stock units will vest in four equal annual installments. Following this award, Hamilton beneficially owned 246,958 shares of common stock, including previously reported shares underlying restricted stock units, some of which remain subject to vesting conditions.
Arrowhead Pharmaceuticals’ Chief Financial Officer Daniel Joseph Apel reported an equity award of company stock. On January 6, 2026, he acquired 75,000 shares of common stock at a price of $0 per share, representing shares underlying restricted stock units. These RSUs will vest in four equal annual installments, meaning portions of the award become fully owned over four years if conditions are met. Following this grant, Apel beneficially owns 176,200 shares of common stock, which includes previously reported RSU-based holdings, some of which remain subject to vesting conditions.
Arrowhead Pharmaceuticals COO Patrick O'Brien reported several stock gifts and a new equity award. On January 6, 2026, he made multiple transactions coded "G" that transferred a total of 2,500 shares of common stock as a gift to relatives at a price of $0 per share, reducing his holdings stepwise in small blocks.
On the same date, he acquired 75,000 shares of common stock coded "A", representing shares underlying restricted stock units (RSUs) that will vest in four equal annual installments. After these transactions, he beneficially owned 547,408 shares of Arrowhead common stock directly, which includes previously reported RSUs, some of which remain subject to vesting conditions.
Arrowhead Pharmaceuticals, Inc. director William Waddill reported open-market sales of company stock under a pre-arranged Rule 10b5-1 trading plan. On 12/19/2025, he sold 2,416 shares of common stock at a weighted average price of $66.66, with individual trades between $66.52 and $67.29. On the same date, he sold an additional 5,451 shares at a weighted average price of $68.01, with trades between $67.58 and $68.48, and 500 shares at a weighted average price of $68.53, with trades between $68.51 and $68.56. After these transactions, Waddill beneficially owned 56,563 shares of Arrowhead Pharmaceuticals common stock, including shares underlying previously reported restricted stock units that remain subject to vesting conditions.
Arrowhead Pharmaceuticals’ Chief Executive Officer and director Christopher Anzalone reported preset stock sales in December 2025. On December 19, 2025, he sold several blocks of Arrowhead common stock, including 3,979 shares at a weighted average price of $66.67, 8,147 shares at $68.01, and 1,319 shares at $68.48. On December 22, 2025, he sold additional blocks of 10,012 shares at a weighted average price of $68.33 and 2,574 shares at $68.85.
The filing states that all of these transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted by the reporting person. After these sales, Anzalone beneficially owns 3,805,926 shares of Arrowhead common stock directly, which includes shares underlying previously reported restricted stock units that continue to be subject to vesting conditions.
Arrowhead Pharmaceuticals director reports planned stock sales under a Rule 10b5-1 trading plan. On 12/19/2025, the reporting person sold three blocks of Arrowhead common stock: 3,090 shares at a weighted average price of $66.7, 6,083 shares at a weighted average price of $68.04, and 827 shares at a weighted average price of $68.48.
The filing states these sales were made under a pre‑established 10b5-1 trading plan adopted in accordance with securities regulations. After these transactions, the reporting person beneficially owns 33,600 shares of Arrowhead common stock, which includes shares underlying restricted stock units that remain subject to vesting conditions.
Arrowhead Pharmaceuticals reported an insider equity award for one of its directors. On 12/16/2025, the director received 7,819 shares of common stock through restricted stock units at a price of $0. These shares will vest in a single installment on the first anniversary of the grant date, conditioned on the director’s continued service with the company. Following this grant, the director beneficially owns 46,215 shares of Arrowhead Pharmaceuticals common stock in direct ownership.
Arrowhead Pharmaceuticals director reports new stock award. A board member of Arrowhead Pharmaceuticals received 7,819 shares of common stock on 12/16/2025 through restricted stock units. These shares were acquired at a stated price of $0, reflecting an equity grant rather than an open-market purchase. After this award, the director beneficially owns 43,600 shares of Arrowhead common stock directly.
The 7,819 shares represent underlying restricted stock units that will vest in a single installment on the first anniversary of the grant date, as long as the director continues to serve the company through that date. This filing documents the equity-based compensation granted to the director and updates the total number of shares reported as beneficially owned.
Arrowhead Pharmaceuticals director reports stock grant. A director of Arrowhead Pharmaceuticals, Inc. reported receiving 7,819 shares of common stock on 12/16/2025 at a price of $0. These shares represent restricted stock units that will vest in a single installment on the first anniversary of the grant date, as long as the director continues to serve the company through that date.
After this grant, the director beneficially owns 64,930 shares of Arrowhead common stock in direct ownership. The filing indicates it was made by a single reporting person serving as a director of the company.
Arrowhead Pharmaceuticals reported insider equity activity by its chief executive officer and director in December 2025. On December 12, 2025, he received 180,000 shares underlying restricted stock units, which will vest in four equal annual installments.
On December 15 and 16, 2025, he sold multiple blocks of common stock, including 100,532 shares at a weighted average price of $68.67 and 21,321 shares at $69.28, exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. After these transactions, he beneficially owned 3,916,957 Arrowhead common shares, which include previously reported shares underlying restricted stock units that remain subject to vesting conditions.